Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer-Reference-Cited by-同舟云学术

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer

Published:2021-11 Issue: Volume:Volume 13 Page:8179-8189
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Fasching Peter A,Delea Thomas E,Lu Yen-Shen,De Boer Richard,Hurvitz Sara A,Moynahan Aaron,Chandiwana David,Lanoue Brad,Hu Huilin,Thuerigen Astrid,O'Shaughnessy Joyce

Publisher

Informa UK Limited

Subject

Oncology

Reference24 articles.

1. Palbociclib and Letrozole in Advanced Breast Cancer

2. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

3. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

4. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

5. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany;Cost Effectiveness and Resource Allocation;2024-03-08

2. Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2− advanced breast cancer;Therapeutic Advances in Medical Oncology;2023-01